Infectious diseases in renal allograft recipients: new developments in therapy and prevention.
D000212:Acyclovir / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology; D003453:Cryptococcosis / Q000209:etiology; D003586:Cytomegalovirus Infections / Q000209:etiology; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000209:etiology* / Q000628:therapy; D016030:Kidney Transplantation; D011020:Pneumonia, Pneumocystis / Q000209:etiology; D011183:Postoperative Complications / Q000517:prevention & control / Q000628:therapy; D011379:Prognosis; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000209:etiology; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014777:Virus Diseases / Q000209:etiology
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D000212:Acyclovir